NEW YORK (dpa-AFX Broker) - The analyst firm Jefferies has lowered its target price for Evotec from 34 to 28 euros, but left its rating at "Buy". In a study published on Friday, analyst Peter Welford explained the new price target by saying that he was not commenting on the risk of the surprising departure of CEO Werner Lanthaler, his share transactions and the question of whether this was a systemic failure of the drug researcher, but was raising his forecast for the weighted average cost of capital. However, he continues to see Evotec on a strong growth path with a convincing valuation./edh/tih

Publication of the original study: 25.01.2024 / 14:17 / ET

First release of the original study: 25.01.2024 / 19:00 / ET

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------